Preliminary study of the use of recombinant proteins for controlling Nosema spp.

MIELGO, P; BARRAGÁN, S; DI GIROLAMO FABIO

Daejeon

Congreso; apimondia 2015; 2015

Apimondia

Fumagillin is the only effective active ingredient against Nosemosis. The need for new molecules that control the disease and quality demands by international markets have led to the search for alternative treatments to control or reduce the incidence of parasitosis. The aim of the study was to evaluate the effect on the development of Nosema spp. recombinant proteins (PR) with immunomodulatory effect and possible toxicity to bees.The 5μg/ml concentrations, 50μg/ml, 125μg/ml and 250μg/ml PR (2 synthetic TLR agonists) were evaluated in sucrose syrup 1: 1; with a positive control (Fumagilina 0.12 μg/ml) and negative (syrup only). Approximately 100 adult bees brood obtained were used, naturally infected with Nosema spp. (Average 7000 spores / intestine initial charge). The bees were kept in boxes experimental incubator at 30 ° C and 60-70% humidity with ad libitum protein supplement. Mortality was recorded daily. At the end of the trial, 3 pools (10 intestines each) for each repetition (n=9 per treatment) were obtained to determine the parasitic current (IP).The IP was inversely proportional to the dose of PR, except the dose 250μg/ml, where the mortality was 100%. Maximum survival test at 5th day was observed in the Fumagilina (89%) treatment; of 5μg/ml to 50μg/ml survival increased with dose PR.Fumagilina parasitic intensity treatment showed no significant differences observed in the different doses of PR. The IP negative control was significantly greater than all other treatments.The results indicate that there is a connection between IP-dose longevity in the value range of 5 μg/ml to 125μg/ml. PR administration with food has potential utility as a preventive treatment of the Nosemosis.